Retinol (Vitamin A) - A Complete PG Medicine Review

1. Chemistry and Forms

2. Dietary Sources

• Halibut/Cod liver oil (highest: 900,000 / 18,000 RE per 100 g)
• Ox liver (16,500 RE/100 g)
• Butter, margarine, eggs, milk, fish

• Carrot (1,167 RE), Spinach (607 RE), Mango (313 RE), Papaya (118 RE)

3. Absorption, Transport & Storage

1. Intestine: Dietary retinyl esters + β-carotene absorbed (requires bile, pancreatic enzymes, antioxidant). β-carotene converted to retinol by intestinal enzymes. Retinol esterified (mainly by LRAT - lecithin retinol acyltransferase) → retinyl esters packaged into chylomicrons → lymph → blood.
2. Liver (main store): Retinol taken up via apolipoprotein E receptor. Stored predominantly as retinyl palmitate in perisinusoidal stellate (Ito) cells. >90% of body's reserves in liver. Normal reserves last 6-9 months.
3. Transport to periphery: Retinol released from liver bound to Retinol-Binding Protein (RBP) (synthesized in liver). RBP complexes with transthyretin - this trimolecular complex:
   • Prevents filtration by renal glomerulus (protects against free retinol toxicity)
   • Allows uptake via specific RBP cell-surface receptors
4. Peripheral uptake: Retinol released intracellularly → binds cellular retinol-binding proteins (CRBPs) → can be stored as retinyl ester OR oxidized to retinoic acid.

Exam point: In severe protein deficiency, decreased RBP production prevents mobilization of liver retinol stores - hence VAD can occur despite adequate liver stores!

4. Mechanism of Action (Molecular)

• Retinol → oxidized → Retinoic acid
• Two receptor families: RARs (bind all-trans retinoic acid + 9-cis RA) and RXRs (bind only 9-cis RA)
• RAR/RXR form heterodimers → bind Retinoic Acid Response Elements (RAREs) on DNA
• Regulate transcription: stimulate or repress gene expression
• RXRs also heterodimerize with PPARs, Vitamin D receptors, thyroid hormone receptors - hence broad metabolic effects

5. Functions - HIGH-YIELD

A. Vision (Retinal form)

• Rhodopsin (rod cells) = 11-cis retinal + opsin - responsible for dim/dark light vision
• On light exposure: 11-cis retinal → all-trans retinal + opsin (bleaching) → triggers G-protein (transducin) → nerve impulse
• Regeneration: all-trans retinal → all-trans retinol → 11-cis retinol → 11-cis retinal → re-combines with opsin
• Three iodopsins (cone cells) similarly use retinal for color vision

B. Epithelial Cell Differentiation

• Vitamin A maintains mucus-secreting columnar epithelium
• Deficiency → squamous metaplasia (keratinizing epithelium replaces columnar/cuboidal)
• Affects: conjunctiva, cornea, respiratory tract, GI mucosa, urinary tract, skin

C. Immune Function

• Supports barrier defenses (epithelial integrity)
• Required for normal innate and acquired immunity
• Deficiency → increased susceptibility to respiratory, GI, measles infections

D. Growth & Reproduction

• Essential for normal spermatogenesis
• Supports fetal development

E. Metabolic Effects (Retinoic acid)

• Inhibits adipogenesis, stimulates lipid breakdown
• RXR as cofactor of PPARs → linked to insulin sensitivity and thiazolidinedione drug action

6. Deficiency - Vitamin A Deficiency (VAD)

WHO Classification of Xerophthalmia

Clinical Features in Detail

• Night blindness (XN): Earliest, most common. Mother notices child can't see in dim light
• Conjunctival xerosis (X1A): Conjunctiva dry, non-wettable, muddy, wrinkled - "emerging like sand banks at receding tide" when child ceases to cry
• Bitot's spots (X1B): Triangular, pearly-white/yellowish, foamy, keratinized conjunctival plaques on bulbar conjunctiva - bilateral, temporal > nasal. (In older adults, may be inactive sequelae)
• Corneal xerosis (X2): Cornea dull, dry, non-wettable, eventually opaque
• Keratomalacia (X3B): MEDICAL EMERGENCY - softening/liquefaction of cornea. Cornea may perforate and collapse → irreversible blindness. Fatality rate 4-25%

• Skin: Follicular hyperkeratosis (phrynoderma - "toad skin") - follicular plugging with keratin on extensor surfaces
• Growth retardation, anorexia
• Increased infections (measles, diarrhea, respiratory - leading causes of death in VAD)
• Squamous metaplasia of urinary tract mucosa → pelvic keratinization → keratin debris → renal calculi

Assessment

• Serum retinol: Normal = 1.05-3.50 µmol/L (30-100 µg/dL). Deficient = <0.70 µmol/L (<20 µg/dL or <10 µg/dL in children per Park's)
• Note: Serum retinol is an acute-phase reactant (false low in inflammation) - always measure CRP simultaneously

WHO Community Prevalence Criteria (evidence of public health problem)

7. Treatment

• Day 1: 200,000 IU (110 mg retinol palmitate) orally
• Day 2: 200,000 IU orally
• At discharge (after 2 weeks): 200,000 IU orally

• Children 1-6 years: 200,000 IU orally every 6 months
• Children 6-12 months: 100,000 IU
• Neonates: WHO does NOT recommend routine high-dose supplementation

8. Toxicity (Hypervitaminosis A)

• Nausea, vomiting, abdominal pain, severe headache, dizziness, drowsiness
• Raised ICP → pseudotumor cerebri (papilloedema, diplopia) - does NOT fully resolve after stopping

• Skin: desquamation, dryness, hair loss
• Hepatomegaly → liver fibrosis/cirrhosis (irreversible, unlike other symptoms)
• Bone: periosteal hyperostosis, bone/joint pain, hypercalcemia
• Alopecia, cheilitis
• Elderly more susceptible (delayed lipoprotein clearance → longer retinyl ester exposure)

Exam point: Pseudotumor cerebri and liver cirrhosis are the two complications that persist after stopping excess vitamin A. All others resolve.

9. Quick Recall Summary Table

Incretins - Complete PG Medicine Review for MUHS

1. What is the Incretin Effect?

Exam point: The incretin effect is markedly blunted/reduced in Type 2 Diabetes Mellitus (T2DM). This is one of the core pathophysiological defects in T2DM.

2. The Two Major Incretin Hormones

3. Actions of Incretins

GLP-1 Actions (HIGH-YIELD - multiple effects)

GIP Actions

• ↑ Glucose-dependent insulin secretion
• ↑ Triglyceride storage in adipose tissue
• Less potent compared to GLP-1 in T2DM (β-cell response is blunted)

Exam point: GLP-1's insulin stimulation is glucose-dependent - insulin release is pronounced when glucose is high but attenuated when glucose is normal. This is why GLP-1-based drugs have a LOW risk of hypoglycemia compared to sulfonylureas.

4. Degradation - The DPP-4 Problem

Meal → GLP-1/GIP released from gut
              ↓
        DPP-4 degrades them rapidly (t½ ~2 min)
              ↓
TWO drug approaches to exploit this:
  1. GLP-1 Receptor Agonists → DPP-4 resistant analogues (mimic the incretin effect)
  2. DPP-4 Inhibitors ("Gliptins") → block degradation, ↑ endogenous GLP-1/GIP

5. Drug Classes Based on Incretin Mechanism

CLASS 1: GLP-1 Receptor Agonists ("Incretin Mimetics")

Comparison Table - GLP-1 RAs

• Liraglutide, dulaglutide, semaglutide: approved to reduce cardiovascular mortality in T2DM with CVD
• SELECT trial (semaglutide 2.4mg): 20% ↓ MACE in overweight/obese patients WITHOUT diabetes with CVD
• STEP-HFpEF: semaglutide improved HFpEF symptoms and reduced inflammation

• GI (most common): Nausea, vomiting, diarrhea, constipation (especially on initiation)
• Pancreatitis (avoid in chronic pancreatitis history)
• Thyroid C-cell tumors in rodents → contraindicated in medullary thyroid carcinoma and MEN type 2
• Weight loss (beneficial side effect)

CLASS 2: DPP-4 Inhibitors ("Gliptins") - "Incretin Enhancers"

Comparison Table - DPP-4 Inhibitors

• Oral drug
• Weight neutral (do not cause weight loss, unlike GLP-1 RAs)
• Well tolerated, minimal GI side effects

• Nasopharyngitis, headache (most common)
• Pancreatitis (rare but serious)
• Severe joint pain (arthralgia - arthritis, can be disabling)
• Hypersensitivity reactions
• Saxagliptin: ↑ heart failure hospitalizations

Exam memory trick - "Gliptins": All DPP-4 inhibitors end in "-gliptin". The one safe in renal failure without dose adjustment = Linagliptin (hepatic route).

6. Incretin Defect in T2DM - Pathophysiology

1. GLP-1 secretion is impaired after oral carbohydrate (blunted release from L cells)
2. GIP response is relatively preserved BUT β-cells become resistant to GIP stimulation

7. Incretin-based drugs after Bariatric Surgery

8. Quick Recall Summary

Incretins - MUHS PG Rapid Revision

The Core Concept

This effect is markedly reduced in T2DM - a core pathophysiological defect.

Two Incretin Hormones

GLP-1 Actions - HIGH YIELD

Why low hypoglycemia risk? Insulin stimulation only occurs when glucose is elevated - switches off at normal glucose. Unlike sulfonylureas.

Why Can't We Use Native GLP-1 as a Drug?

STRATEGY 1 → Give DPP-4-resistant GLP-1 analogues = GLP-1 Receptor Agonists
STRATEGY 2 → Block DPP-4 itself = DPP-4 Inhibitors (Gliptins)

Drug Class 1: GLP-1 Receptor Agonists (Incretin Mimetics)

• GI: Nausea, vomiting, diarrhea (most common, especially on initiation)
• Pancreatitis (avoid in h/o chronic pancreatitis)
• Thyroid C-cell tumors in rodents → contraindicated in medullary thyroid carcinoma + MEN2
• Weight loss (beneficial)

Drug Class 2: DPP-4 Inhibitors / "Gliptins" (Incretin Enhancers)

• Nasopharyngitis, headache (most common)
• Pancreatitis (rare)
• Severe disabling arthralgia (class effect)
• Saxagliptin: ↑ heart failure hospitalizations

Incretin Defect in T2DM

1. GLP-1 secretion is impaired after oral carbohydrate
2. β-cells are resistant to GIP (even though GIP levels are near-normal)

Bonus - Bariatric Surgery and Incretins

One-Line Exam Answers

INCRETINS

(Short Answer Question - 15 Marks)

Definition / Introduction (1 mark)

This effect is markedly blunted in Type 2 Diabetes Mellitus (T2DM).

Incretin Hormones (2 marks)

• Secreted by L cells of distal ileum and colon
• Released within minutes of eating
• Fasting level: 5-10 pmol/L → rises to 15-50 pmol/L postprandially
• Half-life: ~2 minutes (degraded by DPP-4 enzyme + renal clearance)

• Secreted by K cells of proximal duodenum and jejunum
• Released in response to glucose + fat (fat is a stronger stimulus)
• Also degraded by DPP-4

Actions of Incretins (3 marks)

GLP-1 Actions (multi-organ):

GIP Actions:

• ↑ Glucose-dependent insulin secretion
• ↑ Triglyceride storage in adipose tissue
• In T2DM: β-cell response to GIP is impaired even though secretion is near-normal

Key point: Insulin stimulation by incretins is glucose-dependent - it is activated when glucose is elevated and switches off at normal levels. This is why incretin-based drugs carry a low risk of hypoglycemia.

Incretin Defect in T2DM (1 mark)

1. GLP-1 secretion is impaired after oral carbohydrate (blunted L-cell response)
2. β-cell resistance to GIP - even though GIP levels are near-normal, the β-cell fails to respond

Incretin-Based Drugs (8 marks)

Strategy 1: GLP-1 Receptor Agonists (Incretin Mimetics)

• GI: Nausea, vomiting, diarrhea, constipation (most common, especially on initiation)
• Pancreatitis (avoid in history of chronic pancreatitis)
• Thyroid C-cell tumors (rodents) → Contraindicated in medullary thyroid carcinoma and MEN type 2
• Weight loss (beneficial in obese T2DM)

Strategy 2: DPP-4 Inhibitors / "Gliptins" (Incretin Enhancers)

• Nasopharyngitis, headache (most common)
• Pancreatitis (rare but serious)
• Severe, disabling arthralgia (joint pain - class effect)
• Hypersensitivity reactions
• Saxagliptin: ↑ heart failure hospitalizations

Clinical Applications Beyond Diabetes (1 mark)

• Obesity: Semaglutide 2.4 mg/week approved for chronic weight management; Tirzepatide 5/10/15 mg/week approved for obesity
• Bariatric surgery: Post-Roux-en-Y gastric bypass, rapid nutrient delivery to distal ileum → massive GLP-1 surge → T2DM remission before significant weight loss
• HFpEF: Semaglutide improved heart failure symptoms and reduced inflammation (STEP-HFpEF trial)
• CKD: GLP-1 RAs show emerging renoprotective benefits (FLOW trial with semaglutide)

Summary Box (for quick recall)

SAQ: INCRETINS (15 Marks)

Definition

Incretin Hormones

• Secreted by L cells of the distal ileum and colon
• Released within minutes of eating, before digested food even reaches L cells (via neurohormonal signals)
• Fasting plasma level: 5-10 pmol/L, rising to 15-50 pmol/L postprandially
• Half-life: approximately 2 minutes - rapidly inactivated by the enzyme DPP-4 and cleared by the kidneys

• Secreted by K cells of the proximal duodenum and jejunum
• Released in response to glucose and fat (fat is a stronger stimulus for GIP than for GLP-1)
• Also rapidly degraded by DPP-4

Physiological Actions

• Pancreatic β-cells: Stimulates insulin secretion in a strictly glucose-dependent manner. This means insulin is released only when blood glucose is elevated - the effect attenuates at normal glucose levels. This is the basis for the low hypoglycemia risk of GLP-1-based drugs.
• Pancreatic α-cells: Suppresses inappropriate glucagon secretion, thereby reducing hepatic glucose output.
• Stomach: Delays gastric emptying, slowing the rate of glucose absorption and blunting postprandial glucose spikes.
• Brain/CNS: Acts centrally to reduce appetite and increase satiety, leading to reduced food intake and weight loss.
• β-cell preservation: Reduces β-cell apoptosis and promotes β-cell proliferation, potentially preserving β-cell mass over time.
• Cardiovascular: Cardioprotective effects demonstrated in multiple clinical trials.

• Stimulates glucose-dependent insulin secretion (similar to GLP-1)
• Promotes triglyceride storage in adipose tissue
• In T2DM, even though GIP secretion is relatively preserved, the β-cell response to GIP is impaired

Incretin Defect in T2DM

1. GLP-1 secretion is reduced after oral carbohydrate ingestion (impaired L-cell function)
2. β-cell resistance to GIP - β-cells fail to respond adequately to GIP even when GIP levels are near-normal

Pharmacological Exploitation - Incretin-Based Drugs

Strategy 1: GLP-1 Receptor Agonists (Incretin Mimetics)

• Exenatide (twice daily SC): Derived from exendin-4, a peptide found in Gila monster venom, with 53% homology to human GLP-1. Should be avoided in severe renal impairment.
• Liraglutide (once daily SC): LEADER trial demonstrated reduction in cardiovascular mortality in T2DM patients with established CVD.
• Dulaglutide (once weekly SC): Proven cardiovascular benefit (REWIND trial).
• Semaglutide (once weekly SC or once daily oral): Most potent GLP-1 RA. The SELECT trial showed a 20% reduction in MACE even in overweight/obese patients without diabetes who had established CVD. STEP-HFpEF trial showed improvement in HFpEF symptoms and reduction in inflammation. Also approved for chronic weight management at 2.4 mg weekly.
• Tirzepatide (once weekly SC): The first dual GLP-1 and GIP receptor agonist. Engineered from native GIP sequence with affinity for both receptors. Produces greater weight loss than GLP-1 RAs alone. FDA approved for T2DM in 2022 and obesity in 2023.

• Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common, especially on initiation - usually transient
• Pancreatitis - avoid in patients with history of chronic pancreatitis
• Thyroid C-cell tumors seen in rodent studies → Contraindicated in medullary thyroid carcinoma and MEN type 2
• Weight loss occurs as a beneficial side effect

Strategy 2: DPP-4 Inhibitors / Gliptins (Incretin Enhancers)

• Sitagliptin: First DPP-4 inhibitor approved. Renally excreted - dose reduction required in CKD.
• Saxagliptin: Metabolized via CYP3A4. Important: associated with increased risk of heart failure hospitalization - should be avoided in patients with or at risk for heart failure.
• Alogliptin: Renally excreted - dose adjustment in CKD.
• Linagliptin: Eliminated via hepatobiliary route. Only DPP-4 inhibitor that does not require dose adjustment in renal failure, making it the preferred gliptin in patients with severe CKD.
• Vildagliptin: Available in India and Europe.

• Nasopharyngitis and headache (most common)
• Pancreatitis (rare but serious)
• Severe, disabling arthralgia - a class effect; can be debilitating
• Hypersensitivity reactions
• Saxagliptin specifically: increased heart failure hospitalizations

Beyond Diabetes - Emerging Uses

• Obesity management: Semaglutide 2.4 mg/week and tirzepatide approved for chronic weight management
• Post-bariatric surgery remission of T2DM: Roux-en-Y gastric bypass causes rapid delivery of nutrients to the distal ileum → massive GLP-1 surge → T2DM remission before major weight loss occurs
• Heart failure (HFpEF): Semaglutide reduces symptoms and inflammation in HFpEF patients
• CKD: GLP-1 RAs show emerging renoprotective benefits

Conclusion

MEAL INGESTED
      ↓
Gut releases GLP-1 (L cells) + GIP (K cells)
      ↓
DPP-4 enzyme degrades them (t½ ~2 min)
      ↓
  Two drug strategies:
  ┌─────────────────────┐    ┌──────────────────────┐
  │ GLP-1 RA            │    │ DPP-4 Inhibitor       │
  │ (DPP-4 resistant    │    │ (blocks DPP-4 →       │
  │ GLP-1 analogue)     │    │ ↑ endogenous GLP-1)   │
  └─────────────────────┘    └──────────────────────┘
         Both → ↑ Glucose-dependent insulin + ↓ Glucagon